Patently Unfair? Two views on the IP vs Competition law debate

19 August 2014
ip-debate

Intellectual Property (IP) and competition law are generally considered distinct specialisms. One involves conferring monopoly power on products or processes. The other scrutinizes, mitigates or prevents such monopoly power. How the two interact has never been more contentious with patent settlements coming under fire from a competition law perspective. Charlotte Tillett, a specialist in patent litigation, and Gustaf Duhs, a specialist competition lawyer, both from Stevens & Bolton, square up to discuss the latest developments and to discuss their opposing (personal and not necessarily deeply held) views on the arguments.

Gustaf Duhs: A hot topic in competition law at the moment is so called “pay for delay” agreements. This is a form of patent dispute settlement agreement in which a generic manufacturer agrees to keep its generic product out of the market of the originator for a specified period of time in return for payment or other consideration. I’ll come on to the competition law issues - but what is the IP angle?

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK









Company Spotlight



More Features in Pharmaceutical